Published in J Clin Invest on June 01, 2008
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Linking human diseases to animal models using ontology-based phenotype annotation. PLoS Biol (2009) 5.17
Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68
Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A (2009) 1.67
Functional specificity of ras isoforms: so similar but so different. Genes Cancer (2011) 1.30
Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci U S A (2013) 1.26
Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells. Dis Model Mech (2008) 1.25
Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet (2009) 1.13
The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm (2009) 1.05
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev (2012) 1.04
Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proc Natl Acad Sci U S A (2011) 1.02
Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev (2009) 1.02
Activated Kras alters epidermal homeostasis of mouse skin, resulting in redundant skin and defective hair cycling. J Invest Dermatol (2010) 0.97
Genetic analysis of Ras genes in epidermal development and tumorigenesis. Small GTPases (2013) 0.95
A New View of Ras Isoforms in Cancers. Cancer Res (2015) 0.90
Signaling to cardiac hypertrophy: insights from human and mouse RASopathies. Mol Med (2012) 0.88
RASopathies: unraveling mechanisms with animal models. Dis Model Mech (2015) 0.84
Vav3 is involved in GABAergic axon guidance events important for the proper function of brainstem neurons controlling cardiovascular, respiratory, and renal parameters. Mol Biol Cell (2010) 0.84
Cardiomyopathies in Noonan syndrome and the other RASopathies. Prog Pediatr Cardiol (2015) 0.82
Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. Oncogene (2013) 0.82
K-RasV14I recapitulates Noonan syndrome in mice. Proc Natl Acad Sci U S A (2014) 0.81
Enhanced human brain associative plasticity in Costello syndrome. J Physiol (2010) 0.81
An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences. Am J Med Genet A (2015) 0.80
HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. Mol Psychiatry (2015) 0.80
Fate and plasticity of the epidermis in response to congenital activation of BRAF. J Invest Dermatol (2014) 0.79
In vivo severity ranking of Ras pathway mutations associated with developmental disorders. Proc Natl Acad Sci U S A (2017) 0.77
Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice. Liver Int (2012) 0.77
In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome. Front Cell Neurosci (2015) 0.76
The impact of the genetic background in the Noonan syndrome phenotype induced by K-Ras(V14I). Rare Dis (2015) 0.75
Thyroid C-Cell Biology and Oncogenic Transformation. Recent Results Cancer Res (2015) 0.75
Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci U S A (1993) 20.33
Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci U S A (1996) 12.92
Molecular mechanisms of human hypertension. Cell (2001) 11.17
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci U S A (1992) 9.19
A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell (1990) 8.10
Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem (1996) 8.08
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet (2001) 6.96
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell (1990) 6.94
The sympathetic control of blood pressure. Nat Rev Neurosci (2006) 6.44
Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature (1986) 6.14
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet (2003) 4.74
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet (2006) 4.68
Germline KRAS mutations cause Noonan syndrome. Nat Genet (2006) 4.48
Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet (2005) 4.47
Dicistronic targeting constructs: reporters and modifiers of mammalian gene expression. Proc Natl Acad Sci U S A (1994) 4.44
NF1 tumor suppressor gene function: narrowing the GAP. Cell (2001) 4.11
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science (2006) 3.96
Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet (2006) 3.81
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet (2006) 3.69
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet (2007) 3.47
Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature (1983) 3.09
Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet (2007) 3.08
Nf1 has an essential role in endothelial cells. Nat Genet (2002) 2.63
Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet (2002) 2.46
Differential expression of the ras gene family in mice. Mol Cell Biol (1987) 2.07
Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet (2000) 2.07
HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A (2006) 1.94
PTPN11 mutations in LEOPARD syndrome. J Med Genet (2002) 1.91
Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet (2006) 1.80
Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet (2006) 1.79
Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet (2006) 1.78
Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci U S A (1990) 1.56
Costello syndrome: an overview. Am J Med Genet C Semin Med Genet (2003) 1.49
Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J (2004) 1.47
Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet (2005) 1.47
Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell (2005) 1.45
HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A (2006) 1.39
HRAS and the Costello syndrome. Clin Genet (2007) 1.31
Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat Med (2006) 1.27
Further delineation of cardiac abnormalities in Costello syndrome. Am J Med Genet (2002) 1.26
Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell (2005) 1.23
New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov (2002) 1.22
pMECA: a cloning plasmid with 44 unique restriction sites that allows selection of recombinants based on colony size. Biotechniques (1998) 1.22
Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype? Am J Med Genet A (2008) 1.21
Gene targeting approaches to analyzing hypertension. J Am Soc Nephrol (1999) 1.18
Effect of renal denervation on dynamic autoregulation of renal blood flow. Am J Physiol Renal Physiol (2004) 1.11
Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am J Physiol Heart Circ Physiol (2003) 1.11
SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet (2007) 1.08
ACE inhibitors in pediatric patients with heart failure. Paediatr Drugs (2006) 1.04
De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet (2007) 1.02
Myocardial storage of chondroitin sulfate-containing moieties in Costello syndrome patients with severe hypertrophic cardiomyopathy. Am J Med Genet A (2005) 1.01
Renal ischemia in the rat stimulates glomerular nitric oxide synthesis. Am J Physiol Regul Integr Comp Physiol (2001) 0.92
Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene. J Hum Genet (2007) 0.86
Detection of altered H-ras proteins in human tumors using western blot analysis. Lab Invest (1989) 0.78
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47
The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature (2009) 7.39
Mammalian cyclin-dependent kinases. Trends Biochem Sci (2005) 5.54
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet (2003) 4.74
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell (2004) 4.39
Cdk1 is sufficient to drive the mammalian cell cycle. Nature (2007) 4.26
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
A pericyte origin of spinal cord scar tissue. Science (2011) 4.12
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell (2010) 3.97
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (2002) 3.77
Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol (2008) 3.31
p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet (2007) 3.30
GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays (2007) 3.26
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun (2010) 2.97
Three-year outcomes for Medicare beneficiaries who survive intensive care. JAMA (2010) 2.87
Programmed cell senescence during mammalian embryonic development. Cell (2013) 2.78
A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet (2009) 2.68
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature (2013) 2.47
Cell cycle kinases in cancer. Curr Opin Genet Dev (2007) 2.46
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell (2011) 2.28
Relationship Between ICU Length of Stay and Long-Term Mortality for Elderly ICU Survivors. Crit Care Med (2016) 2.03
T cell receptor internalization from the immunological synapse is mediated by TC21 and RhoG GTPase-dependent phagocytosis. Immunity (2011) 2.00
Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol (2009) 1.99
CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci (2007) 1.95
Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A (2006) 1.93
The 90S preribosome is a multimodular structure that is assembled through a hierarchical mechanism. Mol Cell Biol (2007) 1.82
Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab (2012) 1.81
What we have learned about pancreatic cancer from mouse models. Gastroenterology (2012) 1.78
Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell (2005) 1.78
Cohesin-SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres. EMBO J (2012) 1.73
Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res (2003) 1.68
Wound healing defect of Vav3-/- mice due to impaired {beta}2-integrin-dependent macrophage phagocytosis of apoptotic neutrophils. Blood (2009) 1.66
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J (2010) 1.66
Exchange factors of the RasGRP family mediate Ras activation in the Golgi. J Biol Chem (2003) 1.63
Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55α,δ phosphatase. Cancer Cell (2010) 1.63
Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene (2003) 1.62
Rac1 function is required for Src-induced transformation. Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. J Biol Chem (2003) 1.60
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle (2011) 1.53
Specific phosphorylation of p120-catenin regulatory domain differently modulates its binding to RhoA. Mol Cell Biol (2006) 1.50
The Rho exchange factors Vav2 and Vav3 favor skin tumor initiation and promotion by engaging extracellular signaling loops. PLoS Biol (2013) 1.50
DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol (2010) 1.49
Functional characterization of Pwp2, a WD family protein essential for the assembly of the 90 S pre-ribosomal particle. J Biol Chem (2004) 1.49
Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion. Cancer Res (2006) 1.49
Structural determinants for the biological activity of Vav proteins. J Biol Chem (2002) 1.49
Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. Hepatology (2013) 1.48
Use of Intensive Care Services for Medicare Beneficiaries Undergoing Major Surgical Procedures. Anesthesiology (2016) 1.47
Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle (2011) 1.45
Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell (2011) 1.44
Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRas(G12V)-driven pancreatic tumourigenesis. Gut (2013) 1.43
Tpx2 controls spindle integrity, genome stability, and tumor development. Cancer Res (2012) 1.39
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol (2006) 1.36
Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab (2005) 1.31
Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat Immunol (2009) 1.30
Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat Med (2006) 1.27
Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J (2008) 1.25
Vav mediates Ras stimulation by direct activation of the GDP/GTP exchange factor Ras GRP1. EMBO J (2003) 1.24
Phosphorylation of serine 188 protects RhoA from ubiquitin/proteasome-mediated degradation in vascular smooth muscle cells. Circ Res (2005) 1.24
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol (2005) 1.24
Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell (2005) 1.23
Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion. Carcinogenesis (2007) 1.23
p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation. Cell Stem Cell (2012) 1.23
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol (2009) 1.22
Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology (2003) 1.21
Vav1 and Rac control chemokine-promoted T lymphocyte adhesion mediated by the integrin alpha4beta1. Mol Biol Cell (2005) 1.21
Global conformational rearrangements during the activation of the GDP/GTP exchange factor Vav3. EMBO J (2005) 1.21
Coronin 1A promotes a cytoskeletal-based feedback loop that facilitates Rac1 translocation and activation. EMBO J (2011) 1.19
The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells. Sci Signal (2012) 1.17
Genetic disruption of aurora B uncovers an essential role for aurora C during early mammalian development. Development (2011) 1.15
Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol (2013) 1.15
Overall Cdk activity modulates the DNA damage response in mammalian cells. J Cell Biol (2009) 1.14
Anti-aging activity of the Ink4/Arf locus. Aging Cell (2009) 1.13
Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med (2006) 1.12
Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res (2008) 1.12
Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci U S A (2013) 1.11
Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol Biol Cell (2007) 1.11
Activation of Vav by the gammaherpesvirus M2 protein contributes to the establishment of viral latency in B lymphocytes. J Virol (2006) 1.11
Interest in BRCA1/2 testing in a primary care population. Prev Med (2002) 1.10